Truist Financial Corp Sells 26,231 Shares of Solventum Corporation $SOLV

Truist Financial Corp lessened its stake in Solventum Corporation (NYSE:SOLV) by 41.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,558 shares of the company’s stock after selling 26,231 shares during the period. Truist Financial Corp’s holdings in Solventum were worth $2,976,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the stock. United Services Automobile Association acquired a new stake in Solventum during the 1st quarter worth $239,000. Woodline Partners LP grew its holdings in Solventum by 40.7% during the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after acquiring an additional 3,377 shares during the period. Intech Investment Management LLC grew its holdings in Solventum by 167.0% during the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock worth $1,268,000 after acquiring an additional 10,425 shares during the period. First Trust Advisors LP grew its holdings in Solventum by 5.8% during the 2nd quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock worth $19,546,000 after acquiring an additional 14,151 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Solventum during the 2nd quarter worth $766,000.

Insider Activity

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were bought at an average cost of $68.03 per share, with a total value of $100,344.25. Following the acquisition, the director owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.24% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on SOLV shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Piper Sandler lowered their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. BTIG Research reaffirmed a “buy” rating and set a $89.00 target price on shares of Solventum in a report on Wednesday, May 6th. UBS Group lowered their target price on shares of Solventum from $82.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Finally, Rothschild & Co Redburn started coverage on shares of Solventum in a report on Tuesday, March 24th. They set a “sell” rating and a $60.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $85.91.

Solventum Stock Performance

SOLV stock opened at $75.10 on Wednesday. The business’s 50-day moving average price is $67.76 and its two-hundred day moving average price is $74.53. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The firm has a market cap of $13.01 billion, a PE ratio of 9.20, a P/E/G ratio of 1.14 and a beta of 0.59. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.